172 related articles for article (PubMed ID: 22249560)
21. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
[TBL] [Abstract][Full Text] [Related]
22. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
23. Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
[TBL] [Abstract][Full Text] [Related]
24. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
25. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
Vaksman O; Davidson B; Tropé C; Reich R
Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
[TBL] [Abstract][Full Text] [Related]
26. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
27. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
[TBL] [Abstract][Full Text] [Related]
28. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
[TBL] [Abstract][Full Text] [Related]
29. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
Gao FF; Krasinskas AM; Chivukula M
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
[TBL] [Abstract][Full Text] [Related]
30. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.
Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE
Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216
[TBL] [Abstract][Full Text] [Related]
31. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
32. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
33. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
[TBL] [Abstract][Full Text] [Related]
34. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.
Davidson B; Holth A; Nguyen MT; Tropé CG; Wu C
Gynecol Oncol; 2013 Feb; 128(2):364-70. PubMed ID: 23099104
[TBL] [Abstract][Full Text] [Related]
35. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R
Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637
[TBL] [Abstract][Full Text] [Related]
36. Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Davidson B; Goldberg I; Givant-Horwitz V; Nesland JM; Berner A; Bryne M; Risberg B; Kopolovic J; Kristensen GB; Tropé CG; van de Putte G; Reich R
Am J Clin Pathol; 2002 Feb; 117(2):225-34. PubMed ID: 11863219
[TBL] [Abstract][Full Text] [Related]
37. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
[TBL] [Abstract][Full Text] [Related]
38. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
39. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
[TBL] [Abstract][Full Text] [Related]
40. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
